The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes.
作者信息
Wong Carrie R, Lim Joseph K
机构信息
Vatche and Tamar Manoukian Division of Digestive Diseases University of California, Los Angeles Los Angeles CA.
Section of Digestive Diseases Yale University School of Medicine New Haven CT.
出版信息
Clin Liver Dis (Hoboken). 2018 Sep 7;12(2):39-44. doi: 10.1002/cld.721. eCollection 2018 Aug.
Abstract
摘要
相似文献
1
The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes.非酒精性脂肪性肝病与心血管疾病结局之间的关联。
Clin Liver Dis (Hoboken). 2018 Sep 7;12(2):39-44. doi: 10.1002/cld.721. eCollection 2018 Aug.
2
Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.非酒精性脂肪性肝病与心血管疾病表型
SAGE Open Med. 2020 Jun 20;8:2050312120933804. doi: 10.1177/2050312120933804. eCollection 2020.
3
Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.非酒精性脂肪性肝病与心血管疾病的关联及治疗（二）。非酒精性脂肪性肝病的治疗。
Clin Investig Arterioscler. 2017 Jul-Aug;29(4):185-200. doi: 10.1016/j.arteri.2016.06.002. Epub 2016 Sep 28.
4
Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis.理想心血管健康与非酒精性脂肪性肝病呈负相关：前瞻性分析。
Am J Med. 2018 Dec;131(12):1515.e1-1515.e10. doi: 10.1016/j.amjmed.2018.07.011. Epub 2018 Aug 1.
5
Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease.慢性肾脏病与非酒精性脂肪性肝病患者的死亡率增加独立相关。
Liver Int. 2019 Feb;39(2):342-352. doi: 10.1111/liv.13992. Epub 2018 Dec 4.
6
[Relationship between ideal cardiovascular behaviors/factors and the prevalence of nonalcoholic fatty liver disease].[理想心血管行为/因素与非酒精性脂肪性肝病患病率之间的关系]
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Jan;36(1):40-4.
7
[The association of cardiovascular risk factors with nonalcoholic fatty liver disease in health checkup examinees].[健康体检者中心血管危险因素与非酒精性脂肪性肝病的关联]
J Prev Med Public Health. 2008 Nov;41(6):407-12. doi: 10.3961/jpmph.2008.41.6.407.
8
Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.非酒精性脂肪性肝病（NAFLD）——腹膜透析患者的一种新的心血管危险因素。
Perit Dial Int. 2016 Jul-Aug;36(4):427-32. doi: 10.3747/pdi.2014.00223. Epub 2015 Oct 16.
9
Nonalcoholic fatty liver disease: a systematic review.非酒精性脂肪性肝病：系统评价。
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.
10
Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.非酒精性脂肪性肝病、与心血管疾病的关联及治疗。（一）非酒精性脂肪性肝病及其与心血管疾病的关联。
Clin Investig Arterioscler. 2017 May-Jun;29(3):141-148. doi: 10.1016/j.arteri.2016.06.003. Epub 2016 Sep 28.
引用本文的文献
1
Fishing for Solutions: How Pre-Conceptional Fish Oil Supplementation in Obese Fathers Reduces Risk of Non-Alcoholic Fatty Liver Disease in Offspring Mice.探寻解决方案：肥胖父亲孕前补充鱼油如何降低子代小鼠患非酒精性脂肪性肝病的风险
Mol Nutr Food Res. 2025 Mar;69(5):e202400452. doi: 10.1002/mnfr.202400452. Epub 2025 Feb 5.
2
European System for Cardiac Operative Risk Evaluation II and Liver Dysfunction.欧洲心脏手术风险评估系统II与肝功能障碍
Biomedicines. 2025 Jan 10;13(1):154. doi: 10.3390/biomedicines13010154.
3
Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study.瘦型与非瘦型非酒精性脂肪性肝病肝硬化患者的死亡率、肝失代偿及心血管结局：一项退伍军人事务部队列研究
Dig Dis Sci. 2025 Feb;70(2):802-813. doi: 10.1007/s10620-024-08764-4. Epub 2025 Jan 8.
4
Improvements in Oral Lichen Planus Following Periodontal Treatment in a Patient With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case Report.代谢功能障碍相关脂肪性肝病患者牙周治疗后口腔扁平苔藓的改善：一例报告
Cureus. 2024 Jul 21;16(7):e65054. doi: 10.7759/cureus.65054. eCollection 2024 Jul.
5
CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis.趋化因子 (C-X-C 基元) 配体 9、白细胞介素 2 受体亚基 β 和分泌磷蛋白 1，动脉粥样硬化和非酒精性脂肪性肝炎合并症模式中的潜在诊断生物标志物。
Sci Rep. 2024 Jul 16;14(1):16364. doi: 10.1038/s41598-024-66287-4.
6
Obesity in Prediabetic Patients: Management of Metabolic Complications and Strategies for Prevention of Overt Diabetes.糖尿病前期患者的肥胖：代谢并发症的管理及预防显性糖尿病的策略
Endocr Metab Immune Disord Drug Targets. 2025;25(1):8-36. doi: 10.2174/0118715303282327240507184902.
7
Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice.人脐带间充质干细胞可减轻饮食诱导的小鼠肥胖及非酒精性脂肪性肝炎相关纤维化。
Heliyon. 2024 Feb 1;10(3):e25460. doi: 10.1016/j.heliyon.2024.e25460. eCollection 2024 Feb 15.
8
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk.治疗代谢功能障碍相关脂肪性肝病（MASLD）及心血管风险增加患者的新治疗方法
Diagnostics (Basel). 2024 Jan 22;14(2):229. doi: 10.3390/diagnostics14020229.
9
Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.纤维化 4 指数评分可预测脂肪性肝病各谱中并存的冠状动脉疾病。
Dig Dis Sci. 2023 Sep;68(9):3765-3773. doi: 10.1007/s10620-023-07987-1. Epub 2023 Jul 1.
10
Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification.运用网络药理学、分子对接和实验验证探索肝爽颗粒治疗非酒精性脂肪性肝炎的分子机制。
Front Pharmacol. 2023 Jan 24;14:1082451. doi: 10.3389/fphar.2023.1082451. eCollection 2023.
本文引用的文献
1
Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.2 型糖尿病合并酒精性或非酒精性脂肪性肝病住院患者的心血管疾病、癌症和死亡率。
Diabetes Care. 2018 Feb;41(2):341-347. doi: 10.2337/dc17-1590. Epub 2017 Nov 22.
2
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
3
Bi-directional analysis between fatty liver and cardiovascular disease risk factors.脂肪肝与心血管疾病危险因素之间的双向分析
J Hepatol. 2017 Feb;66(2):390-397. doi: 10.1016/j.jhep.2016.09.022. Epub 2016 Oct 10.
4
Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.非酒精性脂肪性肝病与主要不良心血管事件的关联：系统评价和荟萃分析。
Sci Rep. 2016 Sep 16;6:33386. doi: 10.1038/srep33386.
5
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.非酒精性脂肪性肝病与心血管疾病发病风险：荟萃分析。
J Hepatol. 2016 Sep;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013. Epub 2016 May 17.
6
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.
7
Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study.经冠状动脉造影患者进行脂肪肝筛查后的长期临床结局：一项前瞻性队列研究。
Hepatology. 2016 Mar;63(3):754-63. doi: 10.1002/hep.28253. Epub 2015 Dec 18.
8
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.阿托伐他汀强化降脂对轻度至中度基线丙氨酸氨基转移酶水平升高的冠心病患者心血管结局的影响。
Int J Cardiol. 2013 Oct 9;168(4):3846-52. doi: 10.1016/j.ijcard.2013.06.024. Epub 2013 Aug 31.
9
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.非酒精性脂肪性肝病伴进展性肝纤维化或肝硬化的自然史：一项国际合作研究。
Hepatology. 2011 Oct;54(4):1208-16. doi: 10.1002/hep.24491. Epub 2011 Aug 9.
10
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.在希腊阿托伐他汀和冠心病评估（GREACE）研究中，对于有冠心病和肝功能异常的患者，长期他汀类药物治疗对心血管事件的安全性和有效性：一项事后分析。
Lancet. 2010 Dec 4;376(9756):1916-22. doi: 10.1016/S0140-6736(10)61272-X. Epub 2010 Nov 23.
Zotero 插件